Education
About Us
Working with TipRanks
Follow Us
Amneal Pharma (AMRX)
:AMRX
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.17Last Year’s EPS
0.16Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 02, 2025
|% Change Since: -1.81%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with significant growth in key areas like CREXONT, biosimilars, and injectables. Despite potential challenges from tariffs and AvKARE channel softness, the company demonstrates robust strategic initiatives and infrastructure expansion, maintaining a positive outlook.Company Guidance
During Amneal Pharmaceuticals' First Quarter 2025 Earnings Call, the company reported strong financial performance with a Q1 revenue of $695 million, a 5% increase from the previous year, and an adjusted EBITDA of $170 million, reflecting a 12% growth. The company's adjusted EPS grew by 50%, driven by broad-based growth across its segments, including a 3% increase in the Specialty segment and a 6% rise in the AvKARE segment revenues. Amneal's product CREXONT, for Parkinson’s disease, exceeded market expectations with a current market share surpassing 1% and is expected to reach over 3% by the end of the year, with U.S. peak sales projected between $300 million to $500 million. Furthermore, the company affirmed its full-year 2025 guidance, anticipating total net revenue between $3 billion and $3.1 billion, adjusted EBITDA of $650 million to $675 million, and adjusted EPS between $0.65 to $0.70, indicating continued confidence in its strategic growth initiatives and operational execution.Strong Q1 Performance
Revenue of $695 million grew 5% and adjusted EBITDA of $170 million grew 12%. Adjusted EPS increased by 50%.
CREXONT Market Success
CREXONT for Parkinson’s disease has exceeded expectations with market share surpassing 1% and expected to reach over 3% by year-end. U.S. coverage doubled to 60% of covered lives.
Biosimilars and Injectables Growth
Biosimilars generated $125 million revenue in 2024 with 5 additional regulatory applications filed this year. Injectables portfolio expanded with new launches like BORUZU.
Strategic Partnership and Infrastructure Expansion
Partnership with Metsera in GLP-1s advancing, with a new peptide manufacturing facility and oral fill and finish production facility under construction.
AvKARE Segment Growth
Expected to reach over $900 million revenue by 2027 driven by new launches across distribution, government, and unit dose channels.
---
AMRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 02, 2025 | $7.74 | $7.97 | +2.97% |
Feb 28, 2025 | $8.38 | $8.67 | +3.46% |
Nov 08, 2024 | $8.61 | $8.73 | +1.39% |
Aug 09, 2024 | $7.77 | $7.65 | -1.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amneal Pharma (AMRX) report earnings?
Amneal Pharma (AMRX) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Amneal Pharma (AMRX) earnings time?
Amneal Pharma (AMRX) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMRX EPS forecast?
AMRX EPS forecast for the fiscal quarter 2025 (Q2) is 0.17.
---
